AzTrials
AzTrials

PterygiumNCT01387971

Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders

An observational study of Pterygium and Dry Eye, run by National Taiwan University Hospital at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Currently, due to the advantage of noninvasive, localized, rapid, painless and easily repeatable of impression specimens, the technique is an ideal method of investigating ocular surface disorders when the diagnosis is not clinically obvious or detecting the post-operative change without tissue damage. Read more about this study

Who is it for?
Ages 12 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Pterygium, Dry Eye, Tumor
How many people
80 participants
Where
1 siteTaiwan
Study dates
Sep 2009to Aug 2012
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: various ocular surface disorders

Who may be able to join

  • various ocular surface disorders

Who cannot join

  • cognitive function disorder
  • extremely ocular surface discomfort

Trial locations and contacts

1 site in 1 country.

Taiwan1 site, 1 recruiting
  • National Taiwan University Hospital, department of Ophthalmology

    Taipei, Taiwan

    Recruiting

Other trials in Taiwan

About this study

Currently, due to the advantage of noninvasive, localized, rapid, painless and easily repeatable of impression specimens, the technique is an ideal method of investigating ocular surface disorders when the diagnosis is not clinically obvious or detecting the post-operative change without tissue damage. Using impression cytology for primary diagnosis and follow-up of ocular surface squamous neoplasia, including after therapy with topical mitomycin C has been well-studied. [29]. In addition to the applications described above, pterygium is another disease of interest. Pterygium, a common disease of ocular surface, has high recurrence rate after surgical excision. [30-33] However, the exact etiology and mechanism for recurrence is unknown. A transformation of the phenotypic characteristics of the conjunctival fibroblasts may play an important role. Due to the concern of improvement in treatment, it is important to explore the change of cytomorphology after pterygium operation, to identify the risk factors of developing recurrence, and, furthermore, to clarify the etiology and mechanism. Some ophthalmologists may think this procedure too time-consuming to be a routine examination in outpatient clinics. [34] However, National Taiwan University Hospital (NTUH), as one of the largest tertiary medical centers in Taiwan, is now in charge of a big part of difficult cases of ocular surface. With the need of further precise diagnosis and delicate clinical skills, the investigators are competent for this meaningful program.

Read the detailed description

Impression cytology is a simple, noninvasive technique that has been widely used to aid in the diagnosis of several disorders of the ocular surface. The first use of impression cytology specimens for diagnosis of ocular surface squamous neoplasia was reported in France in 1954 by Larmande and Timsit. [1] In the English language literature, Egbert et al [2] in 1977 documented the use of cellulose acetate filters to detect goblet cell density in patients with the dry eye syndrome. Traditionally, the cytology specimens were obtained by pressing cellulose acetate (Millipore) filters onto the surface of the globe, then air-dried and stained with PAS. [2] The procedure is usually painless even without anesthesia. The filters remove 1 to 3 superficial cell layers of conjunctiva and cornea.

Since its first applications in ocular surface squamous neoplasia and dry eye syndrome, [1,2] the use of impression cytology has expanded to include the staging of conjunctival squamous metaplasia, [3,4] diagnosis of ocular surface squamous neoplasia, [5-11] and follow-up of ocular surface squamous neoplasia after topical mitomycin-C, [10] limbal stem-cell deficiency, [12,13] specific viral infections, [14-16] vitamin A deficiency, [17,18] epithelial cell storage disorders, [19] allergic disorders, [19] conjunctival melanosis and malignant melanoma, [20] and psoriasis [21]. The technique has the additional advantage of preserving limbal stem cells, which occur in the basal layer of the limbal epithelium and are responsible for renewal of the corneal epithelium throughout life. Since ocular surface squamous neoplasia preferentially involves the limbus, limbal stem cells are potentially reduced in number with each surgical biopsy. The progressive loss of limbal stem cells results in limbal stem-cell deficiency, conjunctivalization of the cornea with corneal opacity. Thus, impression cytology offers a safer alternative to diagnosis than repeated biopsies.

With impression cytology, the morphology of the corneal and conjunctival epithelial cells, their staining behavior, and nuclear/cytoplasmic ratio could be observed in detail. Other important characteristics such as goblet cell density, the degree of keratinization of the epithelial cells, the quality of the cell-to-cell cohesion, and the condensation of the nuclear chromatin could also be detected through proper specimens. [3, 22-26] Furthermore, with the improvement of immunocytochemical staining and confocal microscopy, specimens of impression cytology can be further analyzed for complicated ocular disorder such as cytokeratins 3 and 19 are useful in classification of limbal stem cell deficiency [27] and mucin secretion of goblet cells can be evaluated by confocal microscopy [28].

Conditions
Pterygium, Dry Eye, Tumor
Keywords
impression cytology, ocular surface disorders, ocular surface cells' variation, Limbal insufficiency
Medical subject headings
Pterygium, Dry Eye Syndromes, Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01387971
Study groupRoleWhat they receive
ocular surface disordersvarious ocular surface disorders

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jul 2011 (estimated)
  2. Study startSep 2009
  3. Primary completionAug 2012 (estimated)
  4. Study completionAug 2012 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01387971
Sponsor's protocol ID
200910001R
Status last verified
Apr 2011
First submitted
1 Jul 2011
Last updated
6 Jul 2011
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Pterygium and Dry Eye, run by National Taiwan University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Jul 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Wei-Li Chen, MD (886-2-23123456 ext. 65206, chenweili@ntu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in